XCUR exicuretx.com: יחס שווי שוק לערך בספרים

Exicure, Inc. (XCUR) relies on an innovative system for delivering genetic agents into cells without harming the organism, while awaiting payments from licensees. The company is developing RNA-based drugs to combat immune and skin pathologies in collaboration with biopharma partners. The business is currently undergoing a deep restructuring and a search for new assets, with the metric standing at 7.20. Serving as a valuation tool, the price chart on GURU.Markets confirms the company's current state of transformation.

This ratio determines the premium of a business's market value over its net assets. The metric compares the market share price with the book value to reveal the efficiency of resource management. By analyzing the current price-to-book ratio on GURU.Markets, an investor assesses the risk of capital impairment. For Exicure, Inc. (XCUR), this indicator reflects the market revaluation of the intellectual property regarding its drug delivery platform. The licensing potential of gene therapy forms the company's primary additional capital.